CME; pembrolizumab, dostarlimab, durvalumab, olaparib, T-DXd

Overview
This online CME activity, presented in collaboration with the NCCN, provides an in-depth exploration of guideline-driven care for patients with gynecologic malignancies, with a focus on subtype-specific approaches. Participants will learn to apply evidence-based strategies across lines of therapy and review emerging data that may impact practice guidelines. The program emphasizes practical insights on implementing NCCN recommendations in diverse clinical settings and addresses region-specific considerations to optimize care for patients with gynecologic cancers.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Susana Campos, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Dr. Camposhas reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting fees: Eisai
Nicoletta Colombo, MD, PhD
Director, Gynecologic Oncology Program
EU Institute of Oncology
Milan, Italy
Dr. Colombohas reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting fees: AstraZeneca, BioNTech, Clovis Oncology, Eisai, Gilead, GSK, Imugene, Innovation Bio, Merck, Mersana, MSD, Novocure, OncXerna, Pieris, Roche
Ritu Salani, MD
Division Director, Gynecologic Oncology
University of California Los Angeles
Los Angeles, CA
Dr. Salani has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting fees: Daiichi Sankyo, Eisai, GSK, Merck, Pfizer, Regeneron, Seagen
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Bing-E Xu, PhD, has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Apply guideline-concordant care in subtype-specific gynecologic malignancies
- Develop evidence- and guideline-based treatment strategies across lines of therapy in gynecologic malignancies
- Contextualize emerging data with practice- and guideline-changing potential for patients with gynecologic malignancies
- Utilize region-specific treatment delivery approaches to NCCN Guidelines in patients with gynecologic malignancies
Target Audience
This activity has been designed to meet the educational needs of medical oncologists and gynecologic oncologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with gynecological cancers.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour/0.1 CEUs of pharmacy contact hours.

The Universal Activity Number for this program is JA0006235-0000-24-153-H01-P. This learning activity is knowledge based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). Approval is valid until 12/20/2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from Merck Sharp & Dohme LLC.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 12/20/2024
Expiration Date: 12/20/2025